Literature DB >> 18522895

Effects of nicotine on sensorimotor gating impairment induced by long-term treatment with neurotoxic NMDA antagonism.

Bruce A Rasmussen1, David C Perry, Jahn O'Neil, Kebreten F Manaye, Yousef Tizabi.   

Abstract

In order to develop a model of persistent sensorimotor gating that did not require acute NMDA (N-methyl-D-aspartate) receptor blockade, adult female Sprague-Dawley rats were pre-treated with N-methyl-scopolamine (1 mg/kg s.c.), then administered MK-801 (dizocilpine, 5 mg/kg i.p.) along with two separate doses (5 mg/kg) of pilocarpine. The drug regimen was repeated four and eight days later. Controls received saline in lieu of any drug. Ten days after the last neurotoxic treatment, rats had a significant impairment (reduction) in pre-pulse inhibition (PPI). Each treatment group (neurotoxic treated and control) was then divided into two groups for treatment with saline or 0.5 mg/kg nicotine, administered s.c. twice daily from days 10 to 23. The rats were tested for sensorimotor gating on days 17 and 22 shortly after the morning nicotine administration. Nicotine did not affect the PPI in control animals. On day 17, PPI impairment was sustained in neurotoxically treated rats, regardless of saline or nicotine treatment. On day 22, however, the effect of neurotoxic treatment on PPI was totally absent in saline treated rats, whereas in nicotine treated rats, PPI impairment was still evident. Combination of nicotine and neurotoxic treatment also caused an up-regulation of high affinity nicotinic receptors in the cortex and the thalamus and apparent normalization of low affinity nicotinic receptors in the hippocampus. The findings indicate that muscarinic activation, in conjunction with neurotoxic NMDA receptor antagonism, produces relatively long-term impairment in auditory gating, a result relevant to modeling clinical observations of schizophrenia-associated symptoms. Contrary to expectation, nicotine administration in this model resulted in further impairment rather than amelioration of PPI. The results suggest a sustainable model of PPI impairment and possible role of nicotinic receptors in selective brain regions in this behavior.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522895     DOI: 10.1007/BF03033499

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  70 in total

Review 1.  Glutamate receptors and transporters in the hippocampus in schizophrenia.

Authors:  Paul J Harrison; Amanda J Law; Sharon L Eastwood
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 2.  Nicotine use in schizophrenia: the self medication hypotheses.

Authors:  Veena Kumari; Peggy Postma
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

3.  Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain.

Authors:  Z Z Guan; X Zhang; K Blennow; A Nordberg
Journal:  Neuroreport       Date:  1999-06-03       Impact factor: 1.837

Review 4.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 5.  Neuronal nicotinic receptors: from structure to pathology.

Authors:  C Gotti; F Clementi
Journal:  Prog Neurobiol       Date:  2004-12       Impact factor: 11.685

6.  Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats.

Authors:  Carrie K Jones; Elizabeth Lutz Eberle; David B Shaw; David L McKinzie; Harlan E Shannon
Journal:  J Pharmacol Exp Ther       Date:  2004-12-01       Impact factor: 4.030

7.  Normalization of auditory physiology by cigarette smoking in schizophrenic patients.

Authors:  L E Adler; L D Hoffer; A Wiser; R Freedman
Journal:  Am J Psychiatry       Date:  1993-12       Impact factor: 18.112

8.  An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment.

Authors:  J R Pauly; M J Marks; S D Gross; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

Review 9.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

10.  Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients.

Authors:  Torben Mackeprang; Klaus T Kristiansen; Birte Y Glenthoj
Journal:  Biol Psychiatry       Date:  2002-11-01       Impact factor: 13.382

View more
  2 in total

1.  Effects of nicotine on quinpirole- and dizocilpine (MK-801)-induced sensorimotor gating impairments in rats.

Authors:  Amy A Nespor; Yousef Tizabi
Journal:  Psychopharmacology (Berl)       Date:  2008-07-09       Impact factor: 4.530

2.  Nicotine, Auditory Sensory Memory, and sustained Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait.

Authors:  Verner Knott; Dhrasti Shah; Anne Millar; Judy McIntosh; Derek Fisher; Crystal Blais; Vadim Ilivitsky
Journal:  Front Pharmacol       Date:  2012-09-28       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.